BiotechTube

Rotavirus Vaccine, Live, Oral, Pentavalent

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroenteritis

Conditions

Gastroenteritis, Rotavirus

Trial Timeline

May 1, 2008 → Oct 1, 2008

NCT ID
NCT00496054

About Rotavirus Vaccine, Live, Oral, Pentavalent

Rotavirus Vaccine, Live, Oral, Pentavalent is a phase 3 stage product being developed by Merck for Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00496054. Target conditions include Gastroenteritis, Rotavirus.

What happened to similar drugs?

1 of 10 similar drugs in Gastroenteritis were approved

Approved (1) Terminated (1) Active (8)
✅Bacillus clausii + Oral Rehydration TherapySanofiApproved
🔄mRNA-1403ModernaPhase 3
❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
🔄Prulifloxacin + PlaceboMerckPhase 3
🔄RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00496054Phase 3Completed

Competing Products

20 competing products in Gastroenteritis

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
Placebo + HIL-214HilleVaxPhase 1
19
HIL-214 + PlaceboHilleVaxPhase 2/3
28
HIL-214HilleVaxPhase 2
25
HIL-214 + PlaceboHilleVaxPhase 2/3
20
Benralizumab + PlaceboAstraZenecaPhase 2/3
38
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
32
Rotavirus VaccineMerckPre-clinical
18
RotaTeq (V260) + IPVMerckPhase 3
40
V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
40
Prulifloxacin + PlaceboMerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 1
29
RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3
40
prulifloxacinMerckPhase 3
40
montelukastMerckPre-clinical
26
Bacillus ClausiiSanofiPhase 3
40
Bacillus clausii + Oral Rehydration TherapySanofiApproved
43
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19